chr11-5227020-A-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PS1_ModeratePM2PP5_Very_Strong
The NM_000518.5(HBB):c.2T>A(p.Met1?) variant causes a start lost change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000694 in 1,441,946 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 6.9e-7 ( 0 hom. )
Consequence
HBB
NM_000518.5 start_lost
NM_000518.5 start_lost
Scores
8
5
3
Clinical Significance
Conservation
PhyloP100: 7.93
Genes affected
HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 20 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PS1
Another start lost variant in NM_000518.5 (HBB) was described as [Pathogenic] in Lovd
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-5227020-A-T is Pathogenic according to our data. Variant chr11-5227020-A-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 495986.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-5227020-A-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome AF: 6.94e-7 AC: 1AN: 1441946Hom.: 0 Cov.: 26 AF XY: 0.00 AC XY: 0AN XY: 718728
GnomAD4 exome
AF:
AC:
1
AN:
1441946
Hom.:
Cov.:
26
AF XY:
AC XY:
0
AN XY:
718728
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
beta Thalassemia Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 18, 2019 | Variant summary: HBB c.2T>A (p.Met1Lys) alters the initiation codon and is predicted to result either in absence of the protein or truncation of the encoded protein due to translation initiation at a downstream codon. Missense mutation of the initiation codon is widely regarded as deleterious (p.Met1Val, p.Met1Thr, and p.Met1Arg are internally classified as pathogenic). In the HBB gene, other changes at this codon are pathogenic and mutations in the initiation codon are expected to cause severe BTHAL disease. The nearest downstream ATG is codon 55. It is possible that translation of the mutant mRNA initiates from the single in-frame initiation codon (codon 55) and produces a truncated beta-chain that is highly unstable. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 245874 control chromosomes (gnomAD). c.2T>A has been reported in the literature in heterozygous state (once as a de novo occurrence), in 3 individuals, at least two of them presenting with beta-thalassemia intermedia (Vasseur_2017, Lacan_2005, Waye_1997). Thus, it is expected that in homozygosity and/or compound heterozygosity, this variant is likely to cause BTHAL MJR phenotype. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, no assertion criteria provided | curation | The ITHANET community portal, The Cyprus Institute of Neurology and Genetics | Nov 25, 2019 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Aug 31, 2018 | The variant disrupts the natural start codon, and is therefore predicted to significantly disrupt the protein structure. Found in at least one symptomatic patient, and not found in general population data. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Benign
T;T;.;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Uncertain
D
PROVEAN
Uncertain
D;.;.;D
REVEL
Pathogenic
Sift
Pathogenic
D;.;.;D
Sift4G
Pathogenic
D;.;.;.
Polyphen
D;D;.;.
Vest4
MutPred
Gain of ubiquitination at M1 (P = 0.023);Gain of ubiquitination at M1 (P = 0.023);Gain of ubiquitination at M1 (P = 0.023);Gain of ubiquitination at M1 (P = 0.023);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at